Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases.

Abstract

BACKGROUND Regulations on medicinal products for paediatric use require that pharmacokinetics and safety be characterized specifically in the paediatric population. A previous study established that a 10-mg dose of bilastine in children aged 2 to <12 years provided an equivalent systemic exposure as 20 mg in adults. The current study assessed the safety and… (More)
DOI: 10.1111/pai.12555

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.